Alembic Pharma gets USFDA nod for generic anti-fungal solution

• Alembic Pharmaceuticals received final approval from the USFDA for Efinaconazole Topical Solution (10 per cent).
• The generic medication is therapeutically equivalent to Bausch Health Americas, Inc.'s Jublia Topical Solution (10 per cent).
• Efinaconazole Topical Solution is used for the topical treatment of onychomycosis of the toenail(s).
• Alembic was among the first ANDA applicants with a paragraph IV certification.
• The estimated market size for Efinaconazole Topical Solution is USD 500 million for the 12 months ending December 2025.